In last trading session, Praxis Precision Medicines Inc (NASDAQ:PRAX) saw 0.5 million shares changing hands with its beta currently measuring 2.67. Company’s recent per share price level of $74.49 trading at -$5.05 or -6.35% at ring of the bell on the day assigns it a market valuation of $1.39B. That closing price of PRAX’s stock is at a discount of -23.28% from its 52-week high price of $91.83 and is indicating a premium of 55.69% from its 52-week low price of $33.01.

For Praxis Precision Medicines Inc (PRAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.27. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -2.82 in the current quarter.

Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information

Upright in the red during last session for losing -6.35%, in the last five days PRAX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $74.49 price level, adding 18.88% to its value on the day. Praxis Precision Medicines Inc’s shares saw a change of -3.21% in year-to-date performance and have moved -14.04% in past 5-day. Praxis Precision Medicines Inc (NASDAQ:PRAX) showed a performance of -6.41% in past 30-days.

Wall Street analysts have assigned a consensus price target of 73.61 to the stock, which implies a fall of -1.19% to its current value. Analysts have been projecting 60.3 as a low price target for the stock while placing it at a high target of 75.9. It follows that stock’s current price would jump 19.05% in reaching the projected high whereas dropping to the targeted low would mean a gain of 19.05% for stock’s current value.

Praxis Precision Medicines Inc (PRAX) estimates and forecasts

This year revenue growth is estimated to fall -40.50% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 362.25k for the same. And 9 analysts are in estimates of company making revenue of 264.78k in the next quarter. Company posted 515k and 431k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 45.51% while estimates for its earnings growth in next 5 years are of 14.29%.

Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders

BLACKROCK INC. is the top institutional holder at PRAX for having 1.29 million shares of worth $53.52 million. And as of 2024-06-30, it was holding 6.874 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 1.24 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.5638 of outstanding shares, having a total worth of $51.1 million.

On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 888.06 shares of worth $66.15 million or 4.76% of the total outstanding shares. The later fund manager was in possession of 541.27 shares on Sep 30, 2024 , making its stake of worth around $40.32 million in the company or a holder of 2.90% of company’s stock.